
May 31, 2026
Leica Biosystems Expands AstraZeneca And Daiichi Sankyo Collaboration To Advance AI Driven Lung Cancer Biomarker Research
Leica Biosystems is enhancing its collaboration with AstraZeneca and Daiichi Sankyo to further AI-driven research in lung cancer biomarkers, specifically targeting the TROP2 biomarker in non-small cell lung cancer.The expanded partnership aims to develop an immunohistochemistry (IHC) assay and an image analysis algorithm to evaluate the TROP2 Normalized Membrane Ratio (NMR). This initiative builds on AstraZeneca’s existing computational pathology algorithm, Quantitative Continuous Scoring (QCS),









